Compared with placebo , adjusted mean differences in change from baseline HbA1c at week 24 were -074 % ( 95 % CI -088 to -059 ; p < 00001 ) for empagliflozin 10 mg , -085 % ( -099 to -071 ; p < 00001 ) for empagliflozin 25 mg , and -073 % ( -088 to -059 ; p < 00001 ) for sitagliptin .